Find the Right Market Report

Search thousands of industry reports, market insights, and research studies in one place.

Not sure where to start? Try one of these:
Explore healthcare market intelligence and industry insights
Towards Healthcare

UK Biotechnology Companies Strategic Expansion

Date : 28 May 2026

Top Companies in the UK Biotechnology Market & Their Offerings

UK Biotechnology Market Companies are Oxford Biomedica, Autolus Therapeutics, Adaptimmune Therapeutics, Verona Pharma, Immunocore, Orchard Therapeutics, Silence Therapeutics, Bicycle Therapeutics, Touchlight, Abcam, Vaccitech, Avacta Group

Vendor Key Offerings Core Biotechnology Focus
Oxford Biomedica Lentiviral vector development, cell & gene therapy manufacturing, process development services Gene therapy, viral vector platforms, and advanced therapeutics.
Autolus Therapeutics CAR-T cell therapies, cancer immunotherapy platforms, T-cell engineering Cell therapy and oncology biotechnology
Adaptimmune Therapeutics TCR-based T-cell therapies, solid tumor immunotherapies, SPEAR T-cell platform Immunotherapy and cancer treatment innovation
Verona Pharma Respiratory disease biologics, COPD treatment development, and inhaled therapeutics. Respiratory biotechnology and drug development
Immunocore TCR bispecific therapies, oncology biologics, infectious disease immunotherapies Immune-oncology and biologics
Orchard Therapeutics Ex vivo gene therapies, rare disease treatments, hematopoietic stem cell therapies Gene therapy for rare genetic diseases
Silence Therapeutics RNA interference (RNAi) therapeutics, siRNA platform technologies Genetic medicine and RNA therapeutics
Bicycle Therapeutics Bicycle toxin conjugates, peptide-based therapeutics, and oncology drug discovery. Precision oncology and peptide therapeutics
Touchlight Synthetic DNA manufacturing, dbDNA™ platform, mRNA vaccine support  DNA technologies and vaccine biotechnology
Abcam Antibodies, biomarkers, assay kits, protein research tools  Research biotechnology and diagnostics
Vaccitech T-cell immunotherapies, vaccine platforms, and infectious disease research Vaccine biotechnology and immunology
Avacta Group Affimer® therapeutics, cancer diagnostics, targeted oncology therapies  Diagnostics and targeted therapeutics

What are the Recent Developments in the UK Biotechnology Market? 

  • In March 2025, Celex Oncology introduced a new investigational therapy focused on regulating sodium imbalance in cancer cells to help manage metastatic disease. Presented at Bio-Europe Spring 2025, the approach combined VGSC inhibitors with monoclonal antibodies. Supported by preclinical findings, the therapy aims to slow cancer progression, improve patient survival, and enhance overall quality of life by making the disease more controllable.
  • In January 2025, Verdiva Bio was established with a €333 million Series A funding round, one of the largest in the UK biotech sector. The company focuses on developing oral GLP-1 receptor agonists for obesity treatment. This major investment reflects strong investor confidence in the UK biotechnology industry and its growing potential in advanced metabolic disorder therapies.

Supply Chain Analysis

Clinical Trials

  • UK biotechnology clinical trials in the UK need approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), along with ethical clearance from a Research Ethics Committee (REC). The country has supported more than 570 industry-led clinical trials recently, reflecting its strong research activity. Streamlined regulatory processes and Life Sciences Investment programs further strengthen the ecosystem.
  • Key Players: AstraZeneca, GlaxoSmithKline (GSK)

Regulatory Approvals

  • In the UK, biotechnology regulations are mainly overseen by the Medicines and Healthcare products Regulatory Agency (MHRA) for medical and therapeutic products, while the Department for Environment, Food & Rural Affairs (DEFRA) regulates agricultural biotechnology applications. The system ensures safety, quality, and compliance across healthcare and agri-biotech sectors.
  • Key Players: AstraZeneca and GSK

Serialization

  • Serialization in the UK biotechnology and pharmaceutical sector involves assigning a unique machine-readable code, such as a GS1 DataMatrix, to product packaging for traceability and safety. After Brexit and the Windsor Framework, Great Britain moved away from the EU Falsified Medicines Directive (FMD) system and developed its own national traceability framework. This ensures better supply chain security and product authenticity.
  • Key Players: AstraZeneca, GSK, and major pharmaceutical manufacturers.

Market Growth

The UK biotechnology market size was estimated at USD 113.41 billion in 2025 and is predicted to increase from USD 126.45 billion in 2026 to approximately USD 336.82 billion by 2035, expanding at a CAGR of 11.5% from 2026 to 2035.

UK Biotechnology Market Size is USD 126.45 Billion in 2026.

Ready to make better
healthcare business decisions?

Speak with a healthcare analyst about your research, consulting, or platform needs.

Talk to an Analyst Contact Sales